$2.51 0.00%
CRDF Stock Price vs. AI Score (Last 150 days)
Data gathered: July 16

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.


Cardiff Oncology
Price $2.51
Target Price Sign up
Volume 463,780
Market Cap $112M
Year Range $0.98 - $5.91
Dividend Yield 0%
Revenue per Employee $146,280
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '241.1M3.1M-2M-10M-11M-0.220
Q4 '23160,0002.7M-5.6M-9.3M-10M-0.210
Q3 '231.2M2.9M-1.7M-9.7M-11M-0.220
Q2 '231.2M4.3M-3.1M-11M-12M-0.250
Q1 '231M3.1M-2.1M-11M-12M-0.250

Insider Transactions View All

PACE GARY W filed to buy 697,761 shares at $1.4.
December 19 '23
PACE GARY W filed to buy 667,761 shares at $1.
November 14 '23
Erlander Mark filed to buy 24,481 shares at $1.4.
November 29 '22
White Lale filed to buy 113,788 shares at $1.6.
September 20 '22
Levine James E. filed to buy 60,000 shares at $1.6.
September 19 '22

What is the Market Cap of Cardiff Oncology?

The Market Cap of Cardiff Oncology is $112M.

How Many People Work at Cardiff Oncology?

As of our latest update, Cardiff Oncology employed approximately 25 people worldwide. However, it's important to note that Cardiff Oncology's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Cardiff Oncology's revenue per employee?

$146,280. To calculate Cardiff Oncology's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Cardiff Oncology?

Currently, the price of one share of Cardiff Oncology stock is $2.51.

How can I analyze the CRDF stock price chart for investment decisions?

The CRDF stock price chart above provides a comprehensive visual representation of Cardiff Oncology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cardiff Oncology shares. Our platform offers an up-to-date CRDF stock price chart, along with technical data analysis and alternative data insights.

Does CRDF offer dividends to its shareholders?

As of our latest update, Cardiff Oncology (CRDF) does not offer dividends to its shareholders. Investors interested in Cardiff Oncology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Cardiff Oncology?

Some of the similar stocks of Cardiff Oncology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.